Latest News

Research for management of benign prostate obstruction (BPO) for adult males remains a cornerstone of urology research. This landscape has witnessed the rise and fall of multiple therapies, both surgical and medical. Our aim was to formally evaluate the publication trends for these interventions over the past 20 years. A systematic search was performed in […]

Fernando Maluf: Thank you very much. Thanks to the organizing committee especially to our editors for the kind invitation, and to talk for the first time for the results of the First Global Prostate Cancer Consensus Conference for Developing Countries. I have no conflict of interest for this talk. So this consensus was built to provide […]

Darren Poon: Thank you for your kind introduction and thank you for the organizing committee for inviting me to this wonderful meeting. It will be my great pleasure to share with you my humble opinion on this topic regarding the pharmacoethnicity and its impact on treatment for prostate cancer patients, especially for those from Asian […]

Colin Pritchard: Well, it’s really an honor to be here. Thanks for the organizers. This was one of my favorite meetings a couple of years ago and I am anticipating that it will be even better this year in 2019.  I’m going to talk very quickly about the state-of-the-art in molecular characterization of advanced prostate […]

Neal Shore: We’ve just concluded the third APCCC, the Advanced Prostate Cancer Consensus meeting in Basel, Switzerland. A fantastic meeting, and it’s a great pleasure to introduce the two co-chairs and the organizers, the founders of APCCC. I’m also here with two great colleagues and friends, Chuck Ryan and Alicia Morgans, but without further ado, […]

The optimal treatment for cisplatin-ineligible patients with metastatic urothelial cancer is unknown. A recent study published by Sadeghi et al. in the Journal of Clinical Oncology1 examined the efficacy of the gemcitabine-eribulin combination in this patient population. Cisplatin-ineligibility was defined as a creatinine clearance <60 ml/min and ≥30ml/min, grade 2 or above hearing loss and grade […]

Patients who achieved a pathologic complete response (pCR) after neoadjuvant chemotherapy (NAC) have a better prognosis compared to patients with pathologic residual disease (pRD). The clinical value of these pathological responses over the long-term to NAC is not well understood. A new article published by Waingankar et al. in Urologic Oncology: Seminars and Original Investigations1 […]

Carcinoma in situ (CIS) is a distinct pathological entity. The significance of histological variants associated with CIS is not well-understood. A recent paper published by Sangoi et al. in The American Journal of Surgical Pathology1 described CIS with plasmacytoid features. These features included an abnormal architecture with cellular rounding, enlarged nuclei with eccentric nuclear localization, […]

Although there are 5 well-described morphologic patterns of (nonglandular) urothelial carcinoma in situ (CIS), we have encountered a novel pattern of flat urothelial carcinoma with plasmacytoid features characterized by a triad of morphologic findings including abnormal architecture with cellular rounding, enlarged nuclei with eccentric nuclear localization, and dense globular eosinophilic cytoplasm. A total of 23 […]